Seeing Corneal Degeneration in A New Light

DALLAS – June 17, 2020 – The molecular changes that lead to Fuchs’ endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT Southwestern scientists shows. This insight into this earliest stage of FECD may eventually lead to new ways of screening for and treating the common condition, which affects an estimated 4 percent of U.S. adults over the age of 40.

Read more

Argonne’s researchers and facilities playing a key role in the fight against COVID-19

Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.

Read more

Choosing Common Pain Relievers: It’s Complicated

About 29 million Americans use over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain. Every year in the U.S., NSAID use is attributed to approximately 100,000 hospitalizations and 17,000 deaths. All of these drugs have benefits and risks, but deciding which one to use is complicated for health care providers and their patients. To assist in clinical decision-making, researchers address cardiovascular risks and beyond, which include gastrointestinal and kidney side effects of pain relievers.

Read more